Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Collaboration › Details

Tecan–JPMorgan Chase: investor conference, 201901 supply service Tecan Group presents at JP Morgan Healthcare Conference 2019

 

Period Period 2019-01-10
Region Region San Francisco, CA
  Country United States (USA)
Organisations Partner, 1st Tecan Group Ltd. (SIX Swiss Exchange: TECN)
  Group Tecan (Group)
  Partner, 2nd J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 37th Annual Healthcare Conference 2019 San Francisco
  Product 2 laboratory automation equipment
Persons Person Martyr, David (Tecan 201202–201903 announced CEO for 10/12 before Leica Microsystems RETIRED 4/19)
  Person 2 Brändle, Martin (Tecan 201201 Head Corporate Communications + Investor Relations)
     

Tecan Group Ltd.. (1/7/19). "Press Release: Tecan to Present at J.P. Morgan Healthcare Conference". Männedorf.

The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will present at J.P. Morgan Healthcare Conference in San Francisco, USA, on January 10, 2019.

The investor presentation by David Martyr, CEO of Tecan, will begin at 9:30 am PST (6:30 pm CET) and will be webcast live. The webcast may be accessed under the "Investor Relations" tab of Tecan's website www.tecan.com.

A replay of the webcast will be available after the presentation and will remain available for 90 days.


About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2017, Tecan generated sales of CHF 548 million (USD 560 million; EUR 494 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).


For further information:

Tecan Group
Martin Braendle
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

   
Record changed: 2019-03-14

Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Tecan (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top